SEARCH

SEARCH BY CITATION

References

  • 1
    Balasubramanian M., Keay J.G. (1996) Comprehensive Heterocyclic Chemistry II. In: KatritzkyA.R., ReesC.W., ScrivenE.F.V., editors. Oxford, UK: Pergamon Press, Vol. 5; p. 5.
  • 2
    Yates F.S. (1984) Comprehensive Heterocyclic Chemistry. In: KatritzkyA.R., ReesC.W., editors. Oxford, UK: Pergamon Press, Vol. 2; p. 2.
  • 3
    Jones G. (1977) Chemistry of Heterocyclic Compounds. Vol. 32, Part I, Quinolines. Chichester, UK: John Wiley & Sons.
  • 4
    Jones G. (1982) Chemistry of Heterocyclic Compounds, Vol. 32, Part II, Quinolines. Chichester, UK: John Wiley & Sons.
  • 5
    Greenhill J.V. (1990) Chemistry of Heterocyclic Compounds, Vol. 32, Part III, Quinolines. John Wiley & Sons, Chichester, UK.
  • 6
    Von Oettingen W.F. (1993) Therapeutic Agents of the Quinoline Group. New York, USA: Chemical Catalog Company Inc.
  • 7
    Desai P.K., Desai P., Machhi D., Desai C.M., Patel D. (1996) Quinoline derivatives as antitubercular/antibacterial agents. Indian J Chem Sect B;35:871873.
  • 8
    Strekowski L., Mokrosz J.L., Honkan V.A., Czarny A., Cegla M.T., Wydra R.L., Patterson S.E., Schinazi R.F. (1991) Synthesis and quantitative structure-activity relationship analysis of 2-(aryl or heteroaryl)quinolin-4-amines, a new class of anti-HIV-1 agents. J Med Chem;34:17391746.
  • 9
    Atwell G.J., Baguley B.C., Denny W.A. (1989) Potential antitumor agents. 57. 2-Phenylquinoline-8-carboxamides as minimal DNA-intercalating antitumor agents with in vivo solid tumor activity. J Med Chem;32:396401.
  • 10
    Abel M.D., Luu H.T., Micetich R.G., Nguyen D.Q., Nukatsuka M., Oreski A.B., Tempest M.L., Daneshtalab M. (1996) Cytotoxic quinolines (Part 1) Azolylalkoxyquinolines and azolylalkyl-4(1H)-quinolines. Drug Des Disc;14:1530.
  • 11
    Abel M.D., Ha C.M., Luu H.T., Micetich R.G., Nguyen D.Q., Oreski A.B., Tempest M.L., Daneshtalab M. (1996) Cytotoxic quinolines (Part 2) Azolylalkylamino and thioquinolines. Drug Des Disc;14:3142.
  • 12
    Abel M.D., Luu H.T., Micetich R.G., Nguyen D.Q., Oreski A.B., Tempest M.L., Daneshtalab M. (1996) Synthesis of Azolylalkoxyquinolines with cytotoxic activity. J Het Chem;33:415420.
  • 13
    Rasoul-Amini S., Khalaj A., Shaffie A., Daneshtalab M., Madadkar-Sobhani A., Fouladdel S., Azizi A. (2006) Antitumor activity of new quinoline derivatives in human breast cancer T47D cells. Int J Canc Res;2:102108.
  • 14
    Scholar E.M. (2000) The chemotherapy of malaria. In: ScholarE.M., PrattW.B., editors. The Antimicrobial Drugs. New York, USA: Oxford University Press; p. 375418.
  • 15
    Johnson J.L., Werbel L.M. (1983) Synthesis and antileishmanial activity of 6-Methoxy-4-methyl-N-(6-(substituted-1-piperazinyl) hexyl)-8-quinolinamines and Related Compounds. J Med Chem;26:185194. and references therein.
  • 16
    Mahato S.B., Mandal N.B., Chattopadhyay S., Nandi G., Luger P., Weber M. (1994) Synthesis of Indolylquinolines under Friedel-Crafts reaction conditions. Tetrahedron;50:1080310812.
  • 17
    Ray S., Sadhukhan P.K., Mandal N.B., Mahato S.B., Majumder H.K. (1997) Dual Inhibition of DNA Topoisomerases of Leishmania donovani by Novel Indolyl Quinolines. Biochem Biophys Res Commun;230:171175.
  • 18
    Sahu N.P., Pal C., Mandal N.B., Banerjee S., Raha M., Kundu A.P., Basu A., Ghosh M., Roy K., Bandyopadhyay S. (2002) Synthesis of a novel quinoline derivative, 2-(2-methylquinolin-4-ylamino)-N-phenylacetamide: A potential antileishmanial agent. Bioorg Med Chem;10:16871693.
  • 19
    Tempone A.G., Pompeu da Silva A.C.M., Brandt C.A., Martinez F.S., Borborema S.E.T., Da Silveira M.A.B., De Andrade H.F. Jr (2005) Synthesis and antileishmanial activities of Novel 3-substituted quinoline. Antimicrob Agents Chemother;49:10761080.
  • 20
    Murray H.W. (2001) Clinical and experimental advances in treatment of visceral leishmaniasis. Antimicrob Agents Chemother;41:21852197.
  • 21
    Croft S.L., Barrett M.P., Urbina J.A. (2005) Chemotherapy of trypanosomiases and leishmaniasis. Trends Parasitol;21:508512.
  • 22
    Croft S.L., Seifert K., Yardley V. (2006) Current scenario of drug development for leishmaniasis. Indian J Med Res;123:399410.
  • 23
    Braga F.G., Coimbra E.S., Matos M.O., Carmo A.M.L., Cancio M.D., Da Silva A.D. (2007) Synthesis and in vitro antileishmanial activity of 6-mercaptopurine derivatives. Eur J Med Chem;42:530537.
  • 24
    Carmo A.M.L., Braga F.G., De Paula M.L., Ferreira A.P., Teixeira H.C., Da Silva A.D., Coimbra E.S. (2008) Synthesis and biological activity of new tricyclic purine derivatives obtained by intramolecular N-7 alkylation. Lett Drug Des Disc;5:122126.
  • 25
    Dacosta C., Coimbra E., Braga F., Dos Reis R., De Almeida M., Da Silva A.D. (2009) Preparation and antileishmanial activity of lipophilic N-alkyl diamines. Biomed Pharmacother;63:4042.
  • 26
    Braga F.G., Da Silva A.D., Coimbra E.S., Matos M.O., Prado M.J.V., Cancio M.D. (2005) Avaliação da Atividade de Derivados de Purinas em Promastigotas de Leishmania amazonensis. Revista de Patologia Tropical;34:12.
  • 27
    Drake N.L., Creech H.J., Garman J.A., Haywood S.T., Peck R.M., Van Hook J.O., Walton E. (1946) Synthetic antimalarials. The preparation of certain 4-amino-quinolines. J Am Chem Soc;68:12081213.
  • 28
    Surrey A.R., Hammer H.F. (1946) Some substituted 4-aminoquinoline derivatives. J Am Chem Soc;68:113116.
  • 29
    Singh T., Stein R.G., Hoops J.F., Biel J.H., Hoya W.K., Cruz D.R. (1970) Antimalarials. 7-chloro4-(substituted amino) quinolines. J Med Chem;4:283286.
  • 30
    Lima N.M., Correia C.S., Leon L.L., Machado G.M., Madeira M.de.F., Santana A.E., Goulart M.O. (2004) Antileishmanial activity of lapachol analogues. Mem Inst Oswaldo Cruz;99:757761.
  • 31
    Santos D.O., Coutinho C.E., Madeira M.F., Bottino C.G., Vieira R.T., Nascimento S.B., Bernardino A., Bourguignon S.C., Corte-Real S., Pinho R.T., Rodrigues C.R., Castro H.C. (2008) Leishmaniasis treatment-a challenge that remains: a review. Parasitol Res;103:110.